This article is more than 5 years old. Information may no longer be current.
Top stories in endocrinology: ADA updates Standards of Care, Janssen submits supplemental application for canagliflozin
Among the top stories in endocrinology last week were the American Diabetes Association’s updating its 2019 Standards of Medical Care to reflect findings from two studies of adults with type 2 diabetes and CVD and Janssen’s submission of a supplemental new drug application to the FDA for canaglifozin after positive renal findings.
Other highlights included reports from Healio’s live coverage of the Endocrine Society annual meeting, including discussions on how oral semaglutide resulted in greater HbA1c reductions after 26 weeks vs. sitagliptin, how a men's birth control pill showed promise in a monthlong study and how women with thyroid antibody positivity who received levothyroxine were no more likely to experience a live birth at 34 weeks of gestation than similar women who received placebo treatment.
ADA updates Standards of Medical Care to reflect REDUCE-IT, DECLARE-TIMI 58 findings
The American Diabetes Association issued revisions to its 2019 Standards of Medical Care in Diabetes to reflect findings from two recent large randomized controlled trials that included adults with type 2 diabetes and established cardiovascular disease. Read more.
Janssen submits supplemental new drug application for canagliflozin after positive renal findings
Janssen submitted a supplemental new drug application to the FDA seeking a new indication for the SGLT2 inhibitor canagliflozin to reduce the risk for end-stage renal disease, the doubling of serum creatinine, and renal or cardiovascular death in adults with type 2 diabetes and chronic kidney disease, according to a company press release. Read more.
Oral semaglutide bests sitagliptin for HbA1c reduction
NEW ORLEANS — Oral semaglutide, as an add-on to metformin with or without a sulfonylurea, resulted in greater HbA1c reductions after 26 weeks compared with sitagliptin, according to new data from the PIONEER 3 trial presented at a meeting. Read more.
Men's birth control pill shows promise in monthlong study
NEW ORLEANS — Healthy men assigned to a daily oral modified testosterone pill for 1 month experienced a decrease in serum testosterone consistent with effective contraception while maintaining androgenic traits such as sexual function, according to results presented at a meeting . Read more.
Levothyroxine fails to decrease pregnancy loss in women with thyroid antibody positivity
NEW ORLEANS — A speaker here said euthyroid women with thyroid antibody positivity prescribed levothyroxine before and during pregnancy were no more likely to experience a live birth at 34 weeks of gestation than similar women assigned to placebo treatment. . Read more.